Literature DB >> 2406202

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.

A V Chobanian1, C C Haudenschild, C Nickerson, R Drago.   

Abstract

The effects of 9 months of orally administered captopril (25-50 mg/kg body wt/day) on aortic atherosclerosis was examined in normotensive Watanabe heritable hyperlipidemic rabbits. Captopril caused a significant decrease in aortic atherosclerosis. Total aortic surface involvement by lesions was reduced from 48 +/- 3.6% in control Watanabe rabbits to 30 +/- 3.9% with captopril treatment (p less than 0.01). Most of the decrease could be accounted for by a marked reduction in atherosclerosis of descending thoracic aortas from 49 +/- 5.2% to 15 +/- 3.9% in control and captopril-related groups, respectively (p less than 0.001). Significant decrease in cholesterol content of descending thoracic aorta was also observed in captopril-treated rabbits. Microscopic examination of the arterial lesions in captopril-treated animals suggested a relative decrease in cellularity and increase in extracellular matrix as compared with untreated animals. These studies indicate that captopril has a potent antiatherosclerotic action in the Watanabe heritable hyperlipidemic rabbit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406202     DOI: 10.1161/01.hyp.15.3.327

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  52 in total

1.  Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.

Authors:  Aram V Chobanian
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

2.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Authors:  O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.

Authors:  Joshua Abd Alla; Andreas Langer; Sherif S Elzahwy; Gökhan Arman-Kalcek; Thomas Streichert; Ursula Quitterer
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 4.  Pathogenesis of atherosclerosis: state of the art.

Authors:  C C Haudenschild
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  Parallel regulation of arginine transport and nitric oxide synthesis by angiotensin II in vascular smooth muscle cells role of protein kinase C.

Authors:  M Rivera-Correa; P I Altieri; N Escobales
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

Review 6.  The renin-angiotensin system and cardiac remodelling after acute myocardial infarction.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 7.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

8.  The renin-angiotensin system and the heart: a historical review.

Authors:  S J Cleland; J L Reid
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

9.  Effects of angiotensin II on sustained outward currents in rat ventricular myocytes.

Authors:  Hiroyuki Matsuda; Yasutaka Kurata; Sunao Imanishi; Ryoichi Sato; Toshishige Shibamoto
Journal:  Pflugers Arch       Date:  2003-12-18       Impact factor: 3.657

10.  Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits.

Authors:  H Mitani; T Bandoh; J Ishikawa; M Kimura; T Totsuka; S Hayashi
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.